3D Signatures has a proprietary software platform that is designed to analyze an individual's three dimensional
genomic structure to determine a diagnose of what kind of disease/cancer the patient has, how stable or
aggressive the disease is, and how the patient will respond to treatment.
This is very personalized and predictive which is wherethe medical industry is headed.
3D Signatures was listed and started trading Sept. 13. Insiders hold approximately 40% of the issued stock. DXD is well financed and is expected to close it's brokered
placement this week for $3,000,000 @.75 with a warrant exercisable @ .92 cents good for 2 years.
It is worth noting that Knight Therapeutics-TSX-GUD that trades in the $10.00 range is a significant shareholder
of 3D Signatures and their CEO Jonathan Goodman sits on the 3D Signatures advisory board.